Lukang Pharmaceutical receives approval for gefitinib drug

Shandong Lukang Pharmaceutical announced it has received a drug registration certificate for Gefitinib tablets and approval for its Gefitinib API. The Gefitinib tablet, categorized as a Class 4 chemical drug, has been approved under registration number H20254759 and standard YBH15512025. The API approval is under registration number Y20230000332 and standard YBY66082025. Gefitinib is a targeted medication for non-small cell lung cancer (NSCLC) with EGFR mutations. The company invested approximately CNY11.15 million in the development of Gefitinib tablets and CNY9.9 million in the API. The company believes this approval will enhance its market competitiveness by enriching its pharmaceutical product line.